5 months ago
1
Ajanta Pharma has entered into an in-licensing statement with Biocon for Semaglutide.
Under the agreement, Biocon volition proviso Semaglutide to Ajanta for exclusive selling successful 23 countries and semi-exclusive selling successful 3 countries crossed Africa, the Middle East and Central Asia. A GLP-1 receptor agonist, Semaglutide is to amended glycaemic power successful adults. In a associated release, Ajanta Pharma and Biocon said the merchandise patent expires successful astir of these markets successful March 2026.
Ajanta plans to commercialise the products aft receiving the regulatory approvals, which are expected successful precocious 2026 oregon aboriginal 2027.
Ajanta Pharma managing manager Yogesh Agrawal said “GLP-1 therapies person seen accelerated planetary acceptance and person emerged arsenic blockbuster products worldwide. We are excited to spouse with Biocon for Semaglutide and instrumentality this important therapy to the markets wherever Ajanta has beardown on-ground beingness and heavy reach. Confident of gathering Semaglutide into a meaningful and high-growth marque crossed these countries successful the years ahead”.
Semaglutide is the progressive constituent successful Novo Nordisk’s diabetes and value nonaccomplishment drugs Wegovy and Ozempic.
